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Abstract
Background: Huangqi decoction was first described in Prescriptions of the Bureau of Taiping People’s Welfare
Pharmacy in Song Dynasty (AD 1078), and it is an effective recipe that is usually used to treat consumptive disease,
anorexia, and chronic liver diseases. Transforming growth factor beta 1 (TGFb1) plays a key role in the progression
of liver fibrosis, and Huangqi decoction and its ingredients (IHQD) markedly ameliorated hepatic fibrotic lesions
induced by ligation of the common bile duct (BDL). However, the mechanism of IHQD on hepatic fibrotic lesions is
not yet clear. The purpose of the present study is to elucidate the roles of TGFb1 activation, Smad-signaling
pathway, and extracellular signal-regulated kinase (ERK) in the pathogenesis of biliary fibrosis progression and the
antifibrotic mechanism of IHQD.
Methods: A liver fibrosis model was induced by ligation of the common bile duct (BDL) in rats. Sham-operation
was performed in control rats. The BDL rats were randomly divided into two groups: the BDL group and the IHQD
group. IHQD was administrated intragastrically for 4 weeks. At the end of the fifth week after BDL, animals were
sacrificed for sampling of blood serum and liver tissue. The effect of IHQD on the TGFb1 signaling pathway was
evaluated by western blotting and laser confocal microscopy.
Results: Decreased content of hepatic hydroxyproline and improved liver function and histopathology were
observed in IHQD rats. Hepatocytes, cholangiocytes, and myofibroblasts in the cholestatic liver injury released
TGFb1, and activated TGFb1 receptors can accelerate liver fibrosis. IHQD markedly inhibited the protein expression
of TGFb1, TGFb1 receptors, Smad3, and p-ERK1/2 expression with no change of Smad7 expression.
Conclusion: IHQD exert significant therapeutic effects on BDL-induced fibrosis in rats through inhibition of the
activation of TGFb1-Smad3 and TGFb1-ERK1/2 signaling pathways.
Keywords: Ingredients of Huangqi decoction, Cholestatic liver fibrosis, Transforming growth factor beta 1, Smad-
signaling pathway, Extracellular signal-regulated kinase
Background
Cholestasis, which was identified as an important factor
in a variety of chronic liver diseases [1], results in chole-
static liver fibrosis [2]. The main features of cholestatic
liver fibrosis that have been implicated include reduction
of hepatocytes, proliferation of cholangiocytes, activation
of myofibroblasts, and deposition of extracellular matrix
(ECM) [3,4].
Transforming growth factor beta 1 (TGFb1) is a mem-
ber of the TGFb superfamily of cytokines, which is known
to regulate cell differentiation, proliferation, apoptosis,
pro- and anti-inflammatory immune responses, and ECM
remodeling [5-7]. Studies have shown that the expression
increases of TGFb1 and TGFb1 type I receptor (TbRI) is
one pathological basis for initiation and development of
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immunologically-induced fibrosis in bovine serum albu-
min (BSA) [8]. TGFb1 elevates ECM synthesis by increas-
ing collagen gene transcription in activated hepatic stellate
cells (HSCs) [9]. In addition, evidence has indicated that
TGFb1-mediated bile duct epithelial to mesenchymal tran-
sition in hepatic biliary fibrosis [10] and hepatic TGFb1
activity reduction could inhibit cholestatic fibrosis induced
by bile duct ligation (BDL) [11]. Thus, these studies sug-
gest that TGFb1 is an important factor that is involved in
the process of cholestatic liver fibrosis.
TGFb1 signals through transmembrane Ser-Thr kinase
receptors that directly regulate the intracellular Smad
pathway [12]. Smads belong to a unique family of signal
transduction molecules that can either positively or
negatively regulate the transcription of specific genes in
response to TGFb1 signaling [13]. The TGFb1/Smad
signaling pathway plays a prominent role in the activa-
tion of HSCs and the regulation of the production,
degradation, and accumulation of ECM proteins [14].
Extracellular signal-regulated kinase (ERK) is an
important member of the mitogen-activated protein
kinase (MAPK) family. Recently, the ERK signal pathway
has been found to play an important role in regulating
ECM synthesis that was stimulated by TGFb1 in acti-
vated HSCs. Further study has shown that ECM secre-
tion decreased after inhibiting the activation of ERK
[15]. Thus, the TGFb1 signal transduction pathway has
become a new effective target for the prevention and
treatment of hepatic fibrosis [2,16].
Limited pharmacological therapy for cholestatic liver
fibrosis is available, so new therapeutic approaches are
expected. Chinese herbal medicine has recently become a
hot topic among practitioners of Western medicine. The
principles underlying Chinese herbal medicine were estab-
lished over thousands of years on the basis of clinical
experience and practice, while the effective ingredients in
most of these medications have not been identified.
Huangqi decoction, also known as Huangqi Liuyi
decoction, was first described in Prescriptions of the
Bureau of Taiping People’s Welfare Pharmacy in the
Song Dynasty (AD 1078). It consists of Radix Astragali,
Radix Glycyrrhizae, and Fructus Ziziphi Jujubae.
Huangqi decoction has been used for treatment of many
conditions, including consumptive disease, restlessness,
hydrodipsia, anorexia, and chronic liver diseases. The
active ingredients were extracted from Huangqi decoc-
tion. We have demonstrated previously [15,17] that
Huangqi decoction and its ingredients (IHQD) markedly
ameliorated hepatic fibrotic lesions that were induced by
BDL. In this study, we elucidated the roles of TGFb1
activation, Smad-signaling pathway, and ERK in the
pathogenesis of biliary fibrosis progression and the anti-
fibrotic mechanism of IHQD.
Methods
Reagents and antibodies
Methanol, acetonitrile, and water for high-performance
liquid chromatography (HPLC) were purchased from
Merck (Darmstadt, Germany). Prestained protein mar-
ker was purchased from New England Biolabs (Beijing,
China). Anti-cytokeratin 7 (CK 7) (sc-25721) rabbit anti-
body was purchased from Santa Cruz and used in 1:50
dilution. Anti-albumin (Alb) (ab8940) sheep antibody,
anti-a-smooth muscle actin (a-SMA) (ab5694) rabbit
antibody, and anti-TGFb1 (ab27969) mouse antibody
were purchased from Abcam and prepared in 1:200,
1:200, and 1:1000 dilution, respectively. Anti-TbRI
(#3712) rabbit antibody, anti-TbRII (#3713) rabbit anti-
body, anti-Smad3 (#9513) rabbit antibody, anti-p44/42
MAPK (ERK1/2) (#9107) mouse antibody, and anti-
phospho p44/42 MAPK (ERK1/2) (#9106) mouse anti-
body were purchased from Cell Signaling and diluted
1:1000. Anti-phospho Smad3 (1880-1) rabbit antibody
was purchased from Epitomics and used in 1:1000 dilu-
tion. Anti-Smad7 (3670-100) rabbit antibody was pur-
chased from BioVision and diluted 1:1000. Secondary
fluorescence-labeling goat-anti-mouse Cy3 and goat-
anti-rabbit antibody were obtained from Jackson (West
Grove, PA, USA) and used in 1:1000 dilution. Labeled
rabbit-anti-sheep antibody was obtained from KPL and
used in 1:1000 dilution.
Preparation of IHQD
Huangqi decoction consists of crude herbs in the follow-
ing dosage: Radix Astragali (30 g), Radix Glycyrrhizae
(5 g), and Fructus Ziziphi Jujubae (5 g). The herbal
medicines provided by Shanghai Huayu Herbs Co. Ltd.
were accredited by a pharmacologist of Shuguang Hos-
pital. The medicinal herb mixture was extracted by boil-
ing water, and the aqueous extracts were vacuum–dried
(60°C) to obtain a powder. The aqueous extracts were
further extracted by acetic ether and n-butanol, mixed
together, purified by a process using MCI gel column
chromatography, eluted with 30% methanol, and
reclaimed as a dry powder.
IHQD fingerprinting by high-performance liquid
chromatography (HPLC)
A, methanol (HPLC grade, Merck, China); B, water; C,
methanol (> 99.99% HPLC grade, Merck, China); seal
wash, water/methanol (50/50); needle wash, water/
methanol (50/50).
Sample solution
One milliliter of the sample was accurately transferred
(under content uniformity) into a 50 mL volumetric
flask and a suitable volume of methanol was added.
Following this, samples were treated with ultrasonic
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waves for 20 min, placed at room temperature, diluted
to volume with 50% methanol, and mixed well.
Assay
Five microliters of the sample and standard solution
were separately injected into HPLC, the response was
recorded (peak area or height), and calculated. First, the
column was washed with 100% methanol with 690-740
psi system pressure. The mobile phase was methanol
with a flow rate of 1.00 mL/min. Extracted samples
were analyzed by HPLC and washed with methanol
solution for 30 min in a gradient manner at a flow rate
of 1.0 mL/min.
The HPLC fingerprints of the IHQD are illustrated in
Figure 1.
Animals
Male Sprague-Dawley rats (180-220 g) were supplied by
the Experimental Animal Center to Chinese Academy of
Science. The animals were housed in an air-conditioned
room at 25°C with a 12 h dark/light cycle. The rats
received humane care with unlimited access to chow
food and water during the study. All of this study’s proto-
cols were approved by Shanghai University of Traditional
Chinese Medicine’s Animal Ethics Committee.
BDL model of liver fibrosis
Rats were anesthetized with pentobarbital and BDL was
performed as described previously [16]. Briefly, under
sodium pentobarbital anesthesia, the common bile duct
was double-ligated with 3-0 silk thread after a midline
abdominal incision. The common bile duct was exposed
and manipulated but not ligated in the sham control
group.
Grouping of animals and administration
The model rats were randomly divided into 3 experimen-
tal groups: sham control group (n = 8), BDL alone group
(n = 60) and IHQD group (n = 15). The rats in both
sham control group and BDL alone group received water
administration (1 mL per 100 g) for 4 weeks, beginning
1 week after operation. The rats in IHQD group received
IHQD orally at a concentration of 17.276 mg per 100 g
body weight every day for 4 weeks, beginning 1 week
after BDL operation.
Sampling harvesting
Animals in BDL alone group were sacrificed at the end of
1, 2, 3, 4, and 5 weeks after BDL (n = 8-10) for dynamic
study, and the rats in both sham control group and IHQD
group were sacrificed at the fifth weekend after surgery by
pentobarbital anesthesia (50 mg/kg, intraperitoneal injec-
tion). Blood samples were obtained from interior vena
cava, centrifuged at 3000 r/min for 30 min at 4°C after
3 h, and serum was kept at -70°C for liver function tests.
The livers were rapidly removed, and liver tissue was
taken from the right lobe of the liver, fixed in 10% phos-
phate-buffered formaldehyde, routinely processed, and
blocked into paraffin for detection of collagen content by
biochemical methods and image analysis. Some liver tis-
sues were immersed immediately into cyromatrix (Tissue-
Tek OCT, Sakura Finetek, Torrance, CA, USA), while
other liver tissue was snap-frozen in liquid nitrogen and
stored at -70°C.
Histological examination
Hematoxylin and eosin (H&E) stain
Formalin-fixed liver tissues were processed, and 4 μm thick
paraffin sections were stained with H&E for 10 min, rinsed
with water, and then placed in 75% HCl-ethanol for 30 s,
rinsed with water, placed in eosin-ethanol for 1-2 min,
dehydrated, and mounted.
Sirius red stain
Formalin-fixed liver tissues were processed, and 4 μm thick
paraffin sections were stained with Sirius red for 60 min,
rinsed with 100% ethanol, dehydrated, and mounted.
Hydroxyproline content in liver tissue and serum
biochemistry examination
Liver tissue (100 mg) was prepared for hydroxyproline
(Hyp) determination according to a modified method by
Jamall et al. [18]. Briefly, liver samples were homoge-
nized and hydrolyzed in 6 N HCl at 110°C for 18 h.
After filtration of the hydrolysate through a 0.45 mm
Millipore filter, chloramine-T was added to a final con-
centration of 2.5 mM. The mixture was then treated
with 410 mM paradigm ethyl-amino-benzaldehyde and
incubated at 60°C for 30 min. After cooling to room
temperature, the absorbance of samples was read at
560 nm against a reagent blank that contained all
reagents except tissue. The Hyp content in each sample
was determined from a standard and was expressed as
micrograms per gram of wet weight (μg/g).
Serum levels of albumin (Alb), alanine aminotransfer-
ase (ALT), and total bilirubin (TBil) were measured fol-
lowing the instructions provided by the manufacturer.
Laser confocal microscopy
Liver samples were immersed into cyromatrix and cut
into 5 μm thick cryosections. The cryosections were
Table 1 The methanol gradient elution of the mobile
phase
Time (min) A (%) B (%) C (%)
0 0.5 95 4.5
15 2.5 75 22.5
35 4.5 55 40.5
45 8.0 20 72
60 9.5 5.0 85.5
Du et al. BMC Complementary and Alternative Medicine 2012, 12:33
http://www.biomedcentral.com/1472-6882/12/33
Page 3 of 11
kept at room temperature for 10 min, placed in 100%
acetone for 10 min, and washed 3 times with PBS.
Thereafter, the cryosections were incubated with 5%
bovine serum albumin (BSA) at 37°C for 30 min and
incubated with monoclonal anti-TGFb1 primary anti-
body at 37°C for 2.5 h. Slides were then washed 3 times
with PBS and incubated with the secondary Cy3-conju-
































































Figure 1 HPLC fingerprinting of IHQD. HPLC fingerprinting of Radix Glycyrrhizae (a), Radix Astragali (b), and ingredients of Huangqi decoction
(c).
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1 h. After being washed, the sections were incubated
with a-SMA, Alb, or CK 7 primary antibody at 37°C for
2.5 h, incubated with the secondary goat anti-rabbit,
rabbit anti-sheep, or goat anti-rabbit antibody, respec-
tively, at 37°C for 1 h, and covered with mounting med-
ium. Imaging analyses were performed using a Leica
(Mannheim, Germany) DMIRBE inverted stand and
Leica TCS2MP confocal system. A computer-aided mor-
phometric analysis was used to quantitatively determine
the positive staining area. Five fields of view were
selected randomly from every slice, and the even inte-
gration optic density (IOD) value of the positive staining
area was corrected by the blank in the same visual field.
Immunoblot analysis
Liver samples were lysed by RIPA buffer containing
50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% NP-40,
0.1% SDS, 1 mM EDTA, and 1 mM PMSF and homoge-
nized in ice-water for 3 times for 10 s at 10,000 rpm.
The homogenized solution was transferred to a 1.5 mL
Oak Ridge tube containing 0.1 M PMSF (0.1 mL), cen-
trifuged for 10 min at 4°C and 12,000 rpm to obtain
supernatant. Then, the total protein concentration was
determined by Bio-Rad Dc protein Assay Reagent. Pro-
teins were electrophoretically resolved by 10% SDS poly-
acrylamide gel and immobilized on Hybond-ECL
nitrocellulose membranes. TRIS buffered saline (20 mM
TRIS, 150 mM NaCl, pH 7.4) with 0.1% Tween-20 and
5% non-fat dairy milk was used to block non-specific
binding sites. Blots were incubated with primary antibo-
dies at 4°C overnight and with secondary antibodies at
room temperature for 1 h. Bound antibodies were visua-
lized using an enhanced chemiluminescence kit (Pierce,
Rockford, IL, USA) and exposed to Kodak BioMax film
(Kodak, Rochester, NY, USA).
Statistical analysis
All data were presented as mean ± standard deviation.
Statistical testing was performed with SPSS software
version 12.0. Comparison between groups was performed
with test of homogeneity of variances and one-way analy-
sis of variance (ANOVA), and post hoc analysis was
performed using Bonferroni or Dunnett’s multiple com-
parison test. Correlation coefficients were calculated by
Spearman’s rank correlation method. P-values less than
0.05 were considered statistically significant.
Results
Histological changes
H&E stain showed that no morphological abnormality
was observed in sham control rats. Persistent reduction
of hepatocytes, gradual proliferation of cholangiocytes,
and continuous infiltration of neutrophils were noted in
BDL alone rats. Moreover, hepatocytes aggregate to
flower cricoids at 2 weeks, and tubular structures were
observed at 3, 4, and 5 weeks after BDL. Compared to
these observations that were made in rats in BDL alone
group, there were obvious improvements in IHQD
group (Figure 2a).
Sirius red stain showed that collagen staining was scar-
cely observed in sham control liver samples except in the
area around small central venous walls. In BDL alone
rats, extensive peribiliary and interstitial collagen deposits
were evident. However, IHQD markedly inhibited hepatic
collagen accumulation after BDL (Figure 2b).
Changes in serum liver function and liver tissue Hyp
content
Serum ALT activity, TBil, and liver tissue Hyp content
increased gradually, and peaked at the end of the fifth
week, while Alb content decreased gradually and
reached its lowest level at the end of the fifth week in
BDL alone group compared to values observed in sham
control group (p < 0.01). Compared to measurements in
the 5th week BDL alone group, serum ALT activity,
contents of serum TBil, and liver tissue Hyp significantly
declined (p < 0.05, p < 0.01, p < 0.01) and serum Alb
content remarkably increased in IHQD group (p < 0.05)
(Table 2).
Changes in protein expression of TGFb1, a-SMA, Alb, and
CK 7 in liver tissue
As shown in Figure 3a, the myofibroblast marker a-SMA
(green) was seen only in the hepatic central vein wall in the
portal triads of sham control liver, while TGFb1 (red)
staining and double staining for both markers (yellow)
were light. In BDL alone group, positive staining for a-
SMA, TGFb1, and double staining increased gradually with
modeling. a-SMA positive staining was predominantly
localized in the portal triads at 1, 2, and 3 weeks after BDL.
However, strong staining for a-SMA was observed around
proliferated cholangiocytes at 4 and 5 weeks after BDL.
Compared with 5 week BDL alone group, positive staining
for a-SMA, TGFb1, and double staining was significantly
decreased in IHQD group (p < 0.01).
Strong staining for the hepatocyte marker Alb (green)
and faint staining for TGFb1 (red) were observed, but
positive double staining for both markers (yellow) was
completely negative in sham control group (Figure 3b).
With progress of modeling, positive staining for Alb
decreased gradually; however, positive staining for TGFb1
and positive double staining increased gradually. Com-
pared with 5 week BDL alone group, positive staining for
Alb increased significantly, but positive staining for
TGFb1 and positive double staining for them decreased
significantly in IHQD group (p < 0.01).
As shown in Figure 3c, staining for the cholangiocyte
marker CK 7 (green) was completely negative, and
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TGFb1 staining (red) and double staining for both mar-
kers (yellow) were light in sham control group. With
progress of modeling, positive staining for CK 7,
TGFb1, and positive double staining increased gradually,
especially at 4 and 5 weeks after BDL. Compared with
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Figure 2 Liver tissue H&E Staining (× 400) and Sirius red staining (× 100). S, sham control group; 1 W-5 W, one to five weeks BDL alone
groups; Y, IHQD group.
Table 2 Changes of serum liver function and liver tissue hydroxyproline content in each group (mean S.D.)
group n TBil(mg/dl) Alb(g/l) ALT(u/L) Hyp (μg/g wet liver)
sham control group 8 0.90 ± 0.28## 25.62 ± 1.98## 12.92 ± 1.13## 164.90 ± 12.41##
1 week BDL alone group 8 5.24 ± 0.85**# 23.10 ± 2.45## 69.18 ± 2.82**## 292.96 ± 93.68**##
2 week BDL alone group 8 5.51 ± 0.80**# 20.97 ± 0.39**## 31.68 ± 4.00**## 326.93 ± 14.45**##
3 week BDL alone group 8 5.58 ± 0.27** 20.12 ± 1.57**## 38.96 ± 8.15**## 804.70 ± 35.50**##
4 week BDL alone group 8 6.16 ± 0.95** 16.4 ± 3.15**## 56.83 ± 9.96** 808.37 ± 65.93**##
5 week BDL alone group 10 6.72 ± 0.24** 12.48 ± 3.22** 56.38 ± 5.79** 1069.03 ± 69.27**
IHQD group 14 3.08 ± 0.60**## 15.18 ± 2.99**# 48.81 ± 3.57**# 853.85 ± 21.4**##
Note: Compared with sham control group, *p < 0.05, **p < 0.01; compared with 5 week BDL alone group, #p < 0.05, ##p < 0.01. TBil total bilirubin, ALT alanine
aminotransferase, Alb albumin, Hyp hydroxyproline
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TGFb1, and positive double staining was significantly
decreased in IHQD group (p < 0.01).
Correlation of TGFb1 with a-SMA, Alb, and CK 7
The IOD values of TGFb1, a-SMA, and CK 7 positive
staining areas were calculated (Table 3) and the relation-
ships between TGFb1 and a-SMA, TGFb1 and Alb, and
TGFb1 and CK 7 were analyzed. The IOD value of the
TGFb1 positive staining area was positively correlated
with the level of a-SMA (rs = 0.8984, p < 0.01, Figure 4a)
and CK 7 (rs = 0.8572, p < 0.01, Figure 4c), and was nega-
tively correlated with the level of Alb (r = -0.8694, p <
0.01, Figure 4b) in BDL alone group.
3.5 Changes in the protein expression of a-SMA,
TGFb1, TbRI, TbRII, Smad3, phospho-Smad3, Smad7,
ERK1/2, and phospho-ERK1/2 in liver tissue
We observed low levels of protein expression of
TGFb1, TbRI, TbRII, ERK1/2, phospho-ERK1/2, and
Smad7 in sham control liver tissue, and no obvious pro-
tein expression of Smad3, phospho-Smad3, and a-SMA.
Compared to the protein expression levels in sham con-
trol group rats, protein expression of a-SMA, TbRI,
TbRII, Smad3, phospho-Smad3, ERK1/2, and phospho-
ERK1/2 markedly increased with progress of modeling in
BDL alone group; these increases were especially evident
at 4 and 5 weeks after BDL. However, there were no
distinct changes in TGFb1 and Smad7 protein expression
from 1 to 5 weeks in BDL alone group. The levels of pro-
tein expression of all proteins discussed above except
Smad7 were significantly decreased in IHQD compared
to BDL alone (Figure 5).
Discussion
BDL is an established animal model of cholestasis with
complete biliary obstruction and accumulation of multi-
ple primary bile acids in liver and serum [19]. The
changes that are observed in the BDL model of cholesta-
sis parallel those that occur in cholestasis in humans
[20]. A previous study has indicated that TGFb1 plays a
prominent role in stimulating liver fibrogenesis through
myofibroblasts that are derived from HSCs [10] during
the development of chronic liver injury, including inflam-
mation, fibrosis, and regeneration. In this study, IHQD
significantly ameliorated the cholestatic liver fibrosis in
BDL rats, and IHQD inhibited the protein expression of
TGFb1.
TGFb1, a prototype of multifunctional cytokines, has
been proposed to be a “master switch” in the induction
of fibrosis [21]. Upregulation of TGFb1 expression is a
consistent feature of most fibrotic disease [22-24]. Cells,
such as HSCs, Kupffer cells, myofibroblasts, endothelial
cells, and invading mononuclear cells, could synthesize
Figure 3 Changes in TGFb1, a-SMA, Alb, and CK 7 protein expression detected using confocal microscopy (× 200). S, sham control
group; 1 W-5 W, one to five weeks BDL alone groups; Y, IHQD group (a) TGFb1 (red), a-SMA (green), merge (yellow); (b) TGFb1 (red), Alb
(green), merge (yellow); (c) TGFb1 (red), CK 7 (green), merge (yellow).
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and release TGFb1 [12]. Many studies have created a
strong rationale for an antifibrotic strategy in which the
principal objective of treatment is blocking TGFb1.
Our work suggested that hepatocytes, cholangiocytes,
and myofibroblasts could synthesize and release TGFb1.
In return, TGFb1 promoted reduction of hepatocytes,
proliferation of cholangiocytes, and activation of myofi-
broblasts (Figures 2, 3, 5). IHQD suppressed TGFb1 pro-
tein expression and thus suppressed the effects that
TGFb1 protein expression had on these cell types. These
results suggested that TGFb1 was a plausible candidate
that may play a central role in mediating cholestatic
fibrosis, and that suppression of TGFb1 expression may
be an effective target of IHQD antifibrotic injury.
TGFb1 signaling occurs through heteromeric com-
plexes of type I and type II receptors (TbRI, TbRII) and
cytoplasmic protein mediators belonging to the Smad
family [25]. The activation of the receptor complexes
occurs when TbRII transphosphorylates the GS domain
of TbRI. The activated TbRI associates transiently with,
and also phosphorylates, the receptor-regulated Smads
(R-Smads), Smad2 and Smad3. Once phosphorylated, R-
Smads dissociate from the receptor, bind to Smad4, and
enter the nucleus. The activated Smad complex binds to
target promoters in association with DNA-binding cofac-
tors, and recruits coactivators to activate transcription.
Alternatively, activated Smad complex can also recruit
corepressors, which in turn bind histone deacetylases. As
a result, Smads can either positively or negatively regulate
the transcription of specific genes in response to TGFb1
signaling [25-27]. Antagonistic Smad7 competes with R-
Smads for binding sites to activate TbRI and thus pre-
vents the phosphorylation of R-Smads, resulting in recep-
tor degradation [28]. Therefore, Smad7 terminates or
reduces the strength of the TGFb1-R-Smads signal in a
negative feedback loop.
In this study, focusing on the roles of Smad3 and
antagonistic Smad7, we investigated the differential regu-
latory mechanisms of the TGFb1 signal in rats during
chronic cholestatic liver injury. Our data suggested that
in the cholestatic liver injury, hepatocytes, cholangio-
cytes, and myofibroblasts released TGFb1 and activated
TGFb1 receptors. TGFb1 bound its receptor, phosphory-
lated Smad3, and accelerated liver fibrosis. A remarkable
finding noted in other data was that cholestasis induced
TGFb signaling via Smad3 in vivo [29]. In liver wound
healing, Smad3 is required for hepatic stellate cell matrix
production and matrix interactions [9,30], as well as
maximal type I collagen induction [31]. In addition, high-
level expression of Smad7 protein was also observed. In
the process of cholestatic liver fibrosis, Smad7 antago-
nized Smad3-mediated TGFb1 signal in a negative feed-
back loop without interfering with fibrogenesis. This
finding is consistent with previous work [29]. IHQD
markedly inhibited the protein expression of Smad3
without changing Smad7 expression, suggesting that
IHQD ameliorated cholestatic liver fibrosis by preventing
Smad3-mediated TGFb1 signal in a positive feedback
loop.
Recent findings have suggested a more complex para-
digm of TGFb1 signaling wherein Smads interact with
other signaling cascades, including the MAPK pathway
[32]. ERK is an important member of the MAPK family.
A study demonstrated that TGFb signaling that was acti-
vated after BDL was mediated through ERK activation.
The decrease of TGFb1-induced transcriptional activity
by the ERK blockade results from direct suppression of
R-Smad dependent transcriptional activation. In addition,
differential inhibition of phosphorylation at different
Smad serines suggests mechanisms of crosstalk between
the Smad and MAPK pathways, which would account for
partial inhibition of TGFb/Smad signaling by MAPK
pathway inhibitors [33]. These results strongly suggest a
synergizing role for ERK signal in Smad-signaling that is
initiated by TGFb1.
In this study, we found that ERK1/2 was activated after
BDL, and crosstalk between ERK1/2 and the Smad-signal-
ing pathway enhanced TGFb1-dependent responses in
cholestatic fibrosis caused by BDL. IHQD inhibited ERK1/
2 activation after BDL. IHQD may exert its suppressive
Table 3 The average integration optic density (IOD) values of positive staining areas of a-SMA, Alb, CK 7, and TGFb1
in liver tissues (mean ± S.D.)
group n a-SMA Alb CK 7 TGFb1
sham control group 8 0.02 ± 0.01## 0.53 ± 0.03## 0.00 ± 0.00## 0.03 ± 0.01##
1 week BDL alone group 8 0.03 ± 0.01## 0.34 ± 0.02**## 0.06 ± 0.02**## 0.07 ± 0.02*##
2 week BDL alone group 8 0.06 ± 0.01**## 0.30 ± 0.02**## 0.10 ± 0.02**## 0.11 ± 0.03**##
3 week BDL alone group 8 0.14 ± 0.02**## 0.24 ± 0.02**## 0.16 ± 0.02**## 0.15 ± 0.03**##
4 week BDL alone group 8 0.27 ± 0.03**## 0.19 ± 0.02**## 0.19 ± 0.01** 0.17 ± 0.02**
5 week BDL alone group 10 0.36 ± 0.03** 0.14 ± 0.02** 0.21 ± 0.02** 0.20 ± 0.02**
IHQD group 14 0.11 ± 0.02**## 0.28 ± 0.01**## 0.15 ± 0.02**## 0.15 ± 0.03**##
Note: Compared with sham control group, *p < 0.05, **p < 0.01; compared with 5 week BDL alone group, #p < 0.05, ##p < 0.01. a-SMA a-smooth muscle actin,
Alb albumin, CK 7 cytokeratin 7, TGFb1 transforming growth factor b1
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effects on cholestatic liver fibrosis, at least in part, through
suppression of ERK1/2 activation and crosstalk between
ERK1/2 and the Smad-signaling pathway.
The multifunctional characteristics of TGFb1 indicate a
need for tight control of its signaling. Indeed, both positive
and negative regulatory mechanisms have been observed
at nearly every step in the TGFb1 signaling cascade, from
release of biologically active ligands to the Smad-mediated
transcriptional effects [34]. Our results demonstrated that
TGFb1-mediated induction of Smad3, Smad7, and ERK1/
2 was involved in this tight regulation of its fibrosis signals
in cholestatic liver fibrosis. Smad7 expression increased
but did not interfere with fibrogenesis. The TGFb1 signal
through phosphorylation of Smad3 and activation of
ERK1/2 was constantly propagated throughout hepatic
biliary injury.
Understanding the differential regulatory mechanisms
of the TGFb1 signal between physiologic and pathologic
a 









































Figure 4 Correlation of positive staining area of TGFb1 with a-SMA, Alb, and CK 7 protein expression in 1 to 5 weeks BDL alone
group. (a) Correlation analysis between TGFb1 and a-SMA, (b) correlation analysis between TGFb1 and Alb, (c) correlation analysis between
TGFb1 and CK 7.
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situations will be essential in the design of new thera-
peutic approaches for various diseases caused by a
deregulation of the TGFb1 signal. Thus, antagonists of
the TGFb1 signal could be applied in cholestatic liver
fibrosis. Our findings suggested that IHQD suppressed
the cholestatic liver fibrosis by inhibiting TGFb1 signal-
mediated activation of Smad3 and ERK1/2. This pro-
vides scientific evidence for the clinical application of
Huangqi decoction in treatment of cholestatic liver
fibrosis.
Conclusions
Our study indicated that IHQD exerted a significant
therapeutic effect on BDL-induced fibrosis in rats by
inhibiting the activation of TGFb1-Smad3 and TGFb1-
ERK1/2 signaling pathways. These findings provide
scientific evidence for the clinical application of Huangqi
decoction in treatment of cholestatic liver fibrosis.
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